Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  SUPN
Supernus Pharmaceuticals Inc
SUPN
56 / 100
$30.62arrow_drop_down4.31%-$1.38

Performance History

Stocklytics logo
Key Stats
Open$31.98
Prev. Close$32.00
EPS0.02
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.74B
PE Ratio1,531.00
LOWHIGH
Day Range30.48
31.98
52 Week Range21.99
39.09
Ratios
P/B Ratio1.90
Revenue$607.52M
Operating M. %11.56%
Earnings$1.31M
Earnings Growth %-97.83%
EBITDA Margin %16.17%
ROE %0.15%
EPS0.02

Score Breakdown

56vs 55. Market Avg.

All Score 56 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

SUPNMARKET
Value4640
Quality4340
Ownership217
Growth5445
Dividends-38
warning

Supernus Pharmaceuticals Inc's Price growth average in the last 3 years of 0.1% is modest compared to market average of 6.47%. This indicates SUPN could be a bad value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Mr. Jack A. Khattar
Headquarters
Rockville
Employees
612
Exchange
NASDAQ
add Supernus Pharmaceuticals Inc to watchlist

Keep an eye on Supernus Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Supernus Pharmaceuticals Inc's (SUPN) price per share?

The current price per share for Supernus Pharmaceuticals Inc (SUPN) is $30.62. The stock has seen a price change of -$1.38 recently, indicating a -4.31% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Supernus Pharmaceuticals Inc (SUPN)?

For Supernus Pharmaceuticals Inc (SUPN), the 52-week high is $39.09, which is 27.66% from the current price. The 52-week low is $21.99, the current price is 39.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Supernus Pharmaceuticals Inc (SUPN) a growth stock?

Supernus Pharmaceuticals Inc (SUPN) has shown an average price growth of 0.1% over the past three years. It has received a score of 54 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Supernus Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Supernus Pharmaceuticals Inc (SUPN) stock price performance year to date (YTD)?

As of the latest data, Supernus Pharmaceuticals Inc (SUPN) has a year-to-date price change of 10.42%. Over the past month, the stock has experienced a price change of -11.66%. Over the last three months, the change has been 7.51%. Over the past six months, the figure is 23.27%. Looking at a longer horizon, the five-year price change stands at -18.82%.

help
Is Supernus Pharmaceuticals Inc (SUPN) a profitable company?

Supernus Pharmaceuticals Inc (SUPN) has a net income of $1.32M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 72.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 11.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $607.52M, although specific revenue growth data is currently not available. The gross profit is $438.88M. Operating income is noted at $13.4M. Furthermore, the EBITDA is $108.72M.

help
What is the market capitalization of Supernus Pharmaceuticals Inc (SUPN)?

Supernus Pharmaceuticals Inc (SUPN) has a market capitalization of $1.74B. The average daily trading volume is 322.14K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.